Efficacy of Resveratrol in Depression

Russian Academy of Medical Sciences (RAMS)

Status and phase: Completed; Phase 4

Conditions: Depression

Treatments: Drug: Placebos; Drug: Resveratrol Pill

Study type: Interventional

Funder types: Other

Identifiers

NCT03384329

RESV-depression

Details and patient eligibility

About

Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

Enrollment: 30 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (selectively):

• MDD recurrent or with single episode with melancholic features or dysthymia (DSM-5);
• current depression.

Exclusion Criteria (selectively):

• serious or unstable disease;
• antidepressants intake.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

30 participants in 2 patient groups, including a placebo group

Resveratrol Pill

Experimental group

Treatment:

Drug: Resveratrol Pill

Placebo

Placebo Comparator group

Treatment:

Drug: Placebos